HYPER-CVAD COMPARED TO BFM-LIKE CHEMOTHERAPY FOR THE TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. A RETROSPECTIVE SINGLE CENTER ANALYSIS
(Abstract release date: 05/19/16)
EHA Library. El Cheikh J. 06/09/16; 132412; E863
Disclosure(s): Nothing to disclose
Dr. Jean El Cheikh
Contributions
Contributions
Abstract
Abstract: E863
Type: Eposter Presentation
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens.
Aims
In this report, we retrospectively evaluated the outcome of 62 adult ALL patients treated with hyper-CVAD (n=38) and the (i.e. Berlin-Frankfurt-Munster, n =24) BFM-like protocols at the American university of Beirut medical center, Lebanon; between November 2000 and december 2015. Feasibility of allogeneic stem cell transplantation (allo-SCT) for those patients, in terms of efficacy and tolerability was also evaluated.
Methods
The median age was 38 years in the hyper-CVAD group and 20 years in the BFM-like group with a male/female ratio of 50/50 and 54/46, respectively. The majority of cases were B cell in origin (89% in the hyper-CVAD group and 79% in the BFM-like group). Thirteen patients (34%) vs only 2 patients (8%) were positive for Philadelphia chromosome (Ph+) in both groups respectively, (p= 0.0744). Eight patients received imatinib (7 vs 1) and five patients received dasatinib (4 vs1) in the first and second group respectively. Other 2 patients received imatinib than dasatinib in the hyper-CVAD group only.The disease risk score was high in 76% of patients in the hyper-CVAD group vs 33% of patients the BFM-like group (p=0.119).
Results
The median follow-up time was 29 months. Fifteen patients (39%) and ten patients (42%) underwent allo-SCT in the hyper-CVAD and BFM-like group respectively. At the last follow up 28 patients (74%) were in complete remission (CR) in the first group vs 18 patients (75%) in the second group. Of those, 20 patients (53%) vs 11 patients (46%) were MRD-negative at the last follow up respectively. The 5-year survival rate was similar in hyper-CVAD group compared to the BFM-like group (63 vs. 62%, p= 0.808) (Figure 1). The 5 years disease free survival (DFS) rate was 29% compared to 28% in the BFM-like group, (p= 0.435) (Figure 2). Both chemotherapies were well tolerated. None of the patients died from drug related toxicity.
Conclusion
Despite the older age and more patients with high risk category and Ph+ in the hyper-CVAD group, this difference was not translated into a difference in outcome between the 2 groups.The hyper-CVAD regimen seems to be feasible for adult patients with ALL in terms of tolerability and efficacy. There is still a need for large, prospective, randomized studies in order to establish the best chemotherapy protocols for adult ALL patients.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Hyper-CVAD
Type: Eposter Presentation
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens.
Aims
In this report, we retrospectively evaluated the outcome of 62 adult ALL patients treated with hyper-CVAD (n=38) and the (i.e. Berlin-Frankfurt-Munster, n =24) BFM-like protocols at the American university of Beirut medical center, Lebanon; between November 2000 and december 2015. Feasibility of allogeneic stem cell transplantation (allo-SCT) for those patients, in terms of efficacy and tolerability was also evaluated.
Methods
The median age was 38 years in the hyper-CVAD group and 20 years in the BFM-like group with a male/female ratio of 50/50 and 54/46, respectively. The majority of cases were B cell in origin (89% in the hyper-CVAD group and 79% in the BFM-like group). Thirteen patients (34%) vs only 2 patients (8%) were positive for Philadelphia chromosome (Ph+) in both groups respectively, (p= 0.0744). Eight patients received imatinib (7 vs 1) and five patients received dasatinib (4 vs1) in the first and second group respectively. Other 2 patients received imatinib than dasatinib in the hyper-CVAD group only.The disease risk score was high in 76% of patients in the hyper-CVAD group vs 33% of patients the BFM-like group (p=0.119).
Results
The median follow-up time was 29 months. Fifteen patients (39%) and ten patients (42%) underwent allo-SCT in the hyper-CVAD and BFM-like group respectively. At the last follow up 28 patients (74%) were in complete remission (CR) in the first group vs 18 patients (75%) in the second group. Of those, 20 patients (53%) vs 11 patients (46%) were MRD-negative at the last follow up respectively. The 5-year survival rate was similar in hyper-CVAD group compared to the BFM-like group (63 vs. 62%, p= 0.808) (Figure 1). The 5 years disease free survival (DFS) rate was 29% compared to 28% in the BFM-like group, (p= 0.435) (Figure 2). Both chemotherapies were well tolerated. None of the patients died from drug related toxicity.
Conclusion
Despite the older age and more patients with high risk category and Ph+ in the hyper-CVAD group, this difference was not translated into a difference in outcome between the 2 groups.The hyper-CVAD regimen seems to be feasible for adult patients with ALL in terms of tolerability and efficacy. There is still a need for large, prospective, randomized studies in order to establish the best chemotherapy protocols for adult ALL patients.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Hyper-CVAD
Abstract: E863
Type: Eposter Presentation
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens.
Aims
In this report, we retrospectively evaluated the outcome of 62 adult ALL patients treated with hyper-CVAD (n=38) and the (i.e. Berlin-Frankfurt-Munster, n =24) BFM-like protocols at the American university of Beirut medical center, Lebanon; between November 2000 and december 2015. Feasibility of allogeneic stem cell transplantation (allo-SCT) for those patients, in terms of efficacy and tolerability was also evaluated.
Methods
The median age was 38 years in the hyper-CVAD group and 20 years in the BFM-like group with a male/female ratio of 50/50 and 54/46, respectively. The majority of cases were B cell in origin (89% in the hyper-CVAD group and 79% in the BFM-like group). Thirteen patients (34%) vs only 2 patients (8%) were positive for Philadelphia chromosome (Ph+) in both groups respectively, (p= 0.0744). Eight patients received imatinib (7 vs 1) and five patients received dasatinib (4 vs1) in the first and second group respectively. Other 2 patients received imatinib than dasatinib in the hyper-CVAD group only.The disease risk score was high in 76% of patients in the hyper-CVAD group vs 33% of patients the BFM-like group (p=0.119).
Results
The median follow-up time was 29 months. Fifteen patients (39%) and ten patients (42%) underwent allo-SCT in the hyper-CVAD and BFM-like group respectively. At the last follow up 28 patients (74%) were in complete remission (CR) in the first group vs 18 patients (75%) in the second group. Of those, 20 patients (53%) vs 11 patients (46%) were MRD-negative at the last follow up respectively. The 5-year survival rate was similar in hyper-CVAD group compared to the BFM-like group (63 vs. 62%, p= 0.808) (Figure 1). The 5 years disease free survival (DFS) rate was 29% compared to 28% in the BFM-like group, (p= 0.435) (Figure 2). Both chemotherapies were well tolerated. None of the patients died from drug related toxicity.
Conclusion
Despite the older age and more patients with high risk category and Ph+ in the hyper-CVAD group, this difference was not translated into a difference in outcome between the 2 groups.The hyper-CVAD regimen seems to be feasible for adult patients with ALL in terms of tolerability and efficacy. There is still a need for large, prospective, randomized studies in order to establish the best chemotherapy protocols for adult ALL patients.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Hyper-CVAD
Type: Eposter Presentation
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). However, there have been no prospective randomized trials that directly compare these regimens.
Aims
In this report, we retrospectively evaluated the outcome of 62 adult ALL patients treated with hyper-CVAD (n=38) and the (i.e. Berlin-Frankfurt-Munster, n =24) BFM-like protocols at the American university of Beirut medical center, Lebanon; between November 2000 and december 2015. Feasibility of allogeneic stem cell transplantation (allo-SCT) for those patients, in terms of efficacy and tolerability was also evaluated.
Methods
The median age was 38 years in the hyper-CVAD group and 20 years in the BFM-like group with a male/female ratio of 50/50 and 54/46, respectively. The majority of cases were B cell in origin (89% in the hyper-CVAD group and 79% in the BFM-like group). Thirteen patients (34%) vs only 2 patients (8%) were positive for Philadelphia chromosome (Ph+) in both groups respectively, (p= 0.0744). Eight patients received imatinib (7 vs 1) and five patients received dasatinib (4 vs1) in the first and second group respectively. Other 2 patients received imatinib than dasatinib in the hyper-CVAD group only.The disease risk score was high in 76% of patients in the hyper-CVAD group vs 33% of patients the BFM-like group (p=0.119).
Results
The median follow-up time was 29 months. Fifteen patients (39%) and ten patients (42%) underwent allo-SCT in the hyper-CVAD and BFM-like group respectively. At the last follow up 28 patients (74%) were in complete remission (CR) in the first group vs 18 patients (75%) in the second group. Of those, 20 patients (53%) vs 11 patients (46%) were MRD-negative at the last follow up respectively. The 5-year survival rate was similar in hyper-CVAD group compared to the BFM-like group (63 vs. 62%, p= 0.808) (Figure 1). The 5 years disease free survival (DFS) rate was 29% compared to 28% in the BFM-like group, (p= 0.435) (Figure 2). Both chemotherapies were well tolerated. None of the patients died from drug related toxicity.
Conclusion
Despite the older age and more patients with high risk category and Ph+ in the hyper-CVAD group, this difference was not translated into a difference in outcome between the 2 groups.The hyper-CVAD regimen seems to be feasible for adult patients with ALL in terms of tolerability and efficacy. There is still a need for large, prospective, randomized studies in order to establish the best chemotherapy protocols for adult ALL patients.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Hyper-CVAD
{{ help_message }}
{{filter}}